当前的脂肪肝疾病模型；新的见解、治疗靶点和干预措施。

Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions.

机构信息

Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Division of Endocrinology, Metabolism, & Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

出版信息

Adv Exp Med Biol. 2019;1134:33-58. doi: 10.1007/978-3-030-12668-1_3.

DOI:10.1007/978-3-030-12668-1_3

PMID:30919331

Abstract

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disorders ranging from simple steatosis to steatosis with inflammation and fibrosis. NAFLD is currently the most prevalent chronic liver disease worldwide, with a global prevalence of 25%, and is soon projected to be the leading cause for liver transplantation in the US. Alarmingly, few effective pharmacotherapeutic approaches are currently available to block or attenuate development and progression of NAFLD. Preclinical models are critical for unraveling the complex and multi-factorial etiology of NAFLD and for testing potential therapeutics. Here we review preclinical models that have been instrumental in highlighting molecular and cellular mechanisms underlying the pathogenesis of NAFLD and in facilitating early proof-of-concept investigations into novel intervention strategies.

摘要

非酒精性脂肪性肝病（NAFLD）涵盖了一系列疾病，从单纯性脂肪变性到伴有炎症和纤维化的脂肪变性。NAFLD 是目前全球最常见的慢性肝病，全球患病率为 25%，预计很快将成为美国肝移植的主要原因。令人担忧的是，目前几乎没有有效的药物治疗方法可以阻止或减缓 NAFLD 的发展和进展。临床前模型对于揭示 NAFLD 的复杂和多因素病因以及测试潜在的治疗方法至关重要。在这里，我们回顾了临床前模型，这些模型有助于阐明 NAFLD 发病机制的分子和细胞机制，并促进对新型干预策略的早期概念验证研究。